Gossamer Bio (NASDAQ:GOSS) Stock Rating Lowered by Wall Street Zen

Gossamer Bio (NASDAQ:GOSS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

A number of other brokerages have also recently commented on GOSS. Wedbush raised their price objective on Gossamer Bio from $4.00 to $5.00 and gave the company an “outperform” rating in a research note on Wednesday, August 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Gossamer Bio in a research note on Thursday, September 11th. Finally, Scotiabank started coverage on Gossamer Bio in a research note on Monday, July 14th. They issued a “sector outperform” rating and a $11.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Gossamer Bio presently has a consensus rating of “Buy” and a consensus target price of $8.50.

Gossamer Bio Trading Down 1.0%

NASDAQ GOSS opened at $3.05 on Friday. The business has a 50 day simple moving average of $2.26 and a 200 day simple moving average of $1.53. Gossamer Bio has a one year low of $0.66 and a one year high of $3.60. The stock has a market capitalization of $693.51 million, a P/E ratio of -4.92 and a beta of 1.95. The company has a debt-to-equity ratio of 6.70, a current ratio of 4.40 and a quick ratio of 4.40.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 344.81%.The firm had revenue of $11.49 million during the quarter, compared to analysts’ expectations of $4.12 million. Research analysts expect that Gossamer Bio will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Gossamer Bio

Hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new position in shares of Gossamer Bio in the 2nd quarter worth about $26,000. Banco BTG Pactual S.A. bought a new stake in shares of Gossamer Bio in the 2nd quarter valued at about $27,000. Drive Wealth Management LLC lifted its stake in shares of Gossamer Bio by 52.7% in the 2nd quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after acquiring an additional 8,797 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Gossamer Bio in the 1st quarter valued at about $38,000. Finally, ProShare Advisors LLC bought a new stake in shares of Gossamer Bio in the 2nd quarter valued at about $48,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.